Ildiko Lingvay, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1447216916
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Novo Nordisk AS at 28.4% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 545 payments — averaging $1304.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$202K
- Eli Lilly$78K
- Boehringer Ingelheim$66K
- Novo Nordisk$42K
- AstraZeneca$28K
- Medical Device Business Services, Inc.$26K
- plus $268K from 24 others
Across 16,563 payments — averaging $454.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$5.6M
- Novo Nordisk$803K
- Boehringer Ingelheim$776K
- Sanofi US Services Inc.$223K
- Pfizer$119K
- Amgen$19K
- plus $14K from 3 others
What the payments were for
- Consulting fees$406,12557%
- Speaking & faculty fees$36,3205%
- Travel & lodging$256,25936%
- Food & beverage$12,3422%
- Education$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 116 | $201,634 |
| Eli Lilly | 118 | $77,909 |
| Boehringer Ingelheim | 62 | $66,411 |
| Novo Nordisk | 41 | $42,463 |
| AstraZeneca | 12 | $28,107 |
| Medical Device Business Services, Inc. | 13 | $26,418 |
| Boehringer Ingelheim International GmbH | 4 | $23,467 |
| Pfizer | 10 | $22,863 |
| Sanofi-aventis U.S. LLC | 13 | $21,576 |
| Merck | 14 | $19,191 |
| F. Hoffmann-la Roche AG | 8 | $18,341 |
| Janssen Scientific Affairs, LLC | 14 | $17,989 |
| Astrazeneca UK Limited | 11 | $17,077 |
| Zealand Pharma A/s | 8 | $16,627 |
| AbbVie | 10 | $16,358 |
| Neurocrine Biosciences, Inc. | 9 | $15,656 |
| Genentech, Inc. | 7 | $15,648 |
| Regeneron | 18 | $14,659 |
| Amgen | 5 | $9,392 |
| Lilly USA, LLC | 27 | $9,293 |
| Zealand Pharma US, Inc. | 9 | $7,898 |
| Astrazeneca AB | 2 | $4,948 |
| Shionogi Inc | 5 | $4,853 |
| Boston Scientific | 3 | $4,063 |
| Intercept Pharmaceuticals, Inc. | 1 | $3,850 |
| Johnson & Johnson | 1 | $1,960 |
| Bayer | 1 | $1,880 |
| Dr.reddy's Laboratories,inc. | 1 | $550 |
| GSK | 1 | $83 |
| Corcept Therapeutics | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Echelon Flex$26,129
- Endopath Xcel$26,129
- Harmonic$26,129
- INVOKANA$17,954
- SOLIQUA 100/33$13,797
- JARDIANCE$13,270
- Xultophy 100/3.6$11,720
- Victoza$11,563
- FARXIGA$9,601
- MOUNJARO$8,685
- ZEGALOGUE$7,898
- TOUJEO$7,702
- TRADJENTA$5,213
- STEGLATRO$4,955
- TRULICITY$4,200
- OverStitch Endoscopic Suturing System$4,063
- Dasiglucagon$3,250
- Saxenda$2,168
- ECHELON ENDOPATH$1,960
- Non-Covered$1,880
How this compares
$711,222 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $30,531 |
| OzempicSemaglutide | 17 | $20,131 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,320 |
| SynthroidLevothyroxine Sodium | 26 | $2,824 |
| Levothyroxine Sodium | 55 | $864 |
| Metformin Hcl ErMetformin Hcl | 11 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $66,411 | $30,53125 claims |
| Novo NordiskOzempic | $42,463 | $20,13117 claims |
| AbbVieSynthroid | $16,358 | $2,82426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.